The expression status of TRX, AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer.

Huang, Weisun; Nie, Weiwei; Zhang, Wenwen; Wang, Yanru; Zhu, Aiyu; Guan, Xiaoxiang

Huang, Weisun; Nie, Weiwei; Zhang, Wenwen; Wang, Yanru; Zhu, Aiyu; Guan, Xiaoxiang.

Afiliação

Huang W; Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, People's Republic of China.
Nie W; Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, People's Republic of China.
Zhang W; Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
Wang Y; Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, People's Republic of China.
Zhu A; Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, People's Republic of China.
Guan X; Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, People's Republic of China; Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.

Onco Targets Ther ; 9: 4377-85, 2016.

Article em En | MEDLINE | ID: mdl-27499632

Palavras-chave

androgen receptor; breast cancer; cyclin D1; immunohistochemistry; thioredoxin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Onco Targets Ther Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google